| 73.57 0.72 (0.99%) | 10-09 15:43 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 88.14 |
1-year : | 91.73 |
| Resists | First : | 75.46 |
Second : | 78.54 |
| Pivot price | 73.3  |
|||
| Supports | First : | 70.48 | Second : | 58.64 |
| MAs | MA(5) : | 73.22 |
MA(20) : | 73.51 |
| MA(100) : | 59.54 |
MA(250) : | 50.23 |
|
| MACD | MACD : | 0.6 |
Signal : | 1 |
| %K %D | K(14,3) : | 45.5 |
D(3) : | 43.3 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 78.54 | Low : | 36.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MIRM ] has closed below upper band by 23.3%. Bollinger Bands are 65.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 75.31 - 75.68 | 75.68 - 75.98 |
| Low: | 71.73 - 72.23 | 72.23 - 72.63 |
| Close: | 72.16 - 72.91 | 72.91 - 73.52 |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Sun, 05 Oct 2025
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Wealth Enhancement Advisory Services LLC - MarketBeat
Wed, 24 Sep 2025
Mirum stock is a new Buy at TD Cowen (MIRM:NASDAQ) - Seeking Alpha
Tue, 23 Sep 2025
Atle Fund Management AB Has $5.44 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Wed, 27 Aug 2025
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - businesswire.com
Mon, 11 Aug 2025
Mirum Pharmaceuticals: Q2 Results Continues To Show Positive Momentum (NASDAQ:MIRM) - Seeking Alpha
Thu, 07 Aug 2025
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 3.998e+007 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 6,930 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.286e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13.7 % |
| Return on Assets (ttm) | -4 % |
| Return on Equity (ttm) | -5.2 % |
| Qtrly Rev. Growth | 4.2916e+008 % |
| Gross Profit (p.s.) | 79.13 |
| Sales Per Share | -29.87 |
| EBITDA (p.s.) | 4.18691e+008 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 836 |
| Price to Book value | 0 |
| Price to Sales | -2.48 |
| Price to Cash Flow | 11.76 |
| Dividend | 0 |
| Forward Dividend | 7.5e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|